Mouse relapse model of Clostridium difficile infection

Infection and Immunity

Volumn 79, Issue 7, 2011, Pages 2856-2864

  Sun, Xingmin ^a   Wang, Haiying ^a,b   Zhang, Yongrong ^a,c   Chen, Kevin ^a   Davis, Barbara ^a   Feng, Hanping ^a  

^a TUFTS UNIVERSITY   (United States)

^b SOUTH CHINA UNIVERSITY OF TECHNOLOGY   (China)

^c EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; DEXAMETHASONE; IMMUNOSUPPRESSIVE AGENT; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ANTIBODY RESPONSE; ARTICLE; BACTERIAL SPORE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DIARRHEA; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; PRIMARY INFECTION; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, NEUTRALIZING; BACTERIAL PROTEINS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DISEASE MODELS, ANIMAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; ENTEROTOXINS; MICE; MICE, INBRED C57BL; RECURRENCE; VANCOMYCIN;

EID: 79959413785     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01336-10     Document Type: Article

References (38)

1. Abrams, G. D., M. Allo, G. D. Rifkin, R. Fekety, and J. Silva, Jr. 1980. Mucosal damage mediated by clostridial toxin in experimental clindamycinassociated colitis. Gut 21:493-499.
2. Babcock, G. J., et al. 2006. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect. Immun. 74:6339-6347.
3. Barbut, F., and J. C. Petit. 2000. Epidemiology, risk factors and prevention of Clostridium difficile nosocomial infections. Pathol. Biol. (Paris) 48:745-755.
4. Barbut, F., et al. 2000. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J. Clin. Microbiol. 38:2386-2388.
5. Bartlett, J. G. 2002. Clinical practice.Antibiotic-associated diarrhea. N. Engl. J. Med. 346:334-339.
6. Bartlett, J. G. 2006. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann. Intern. Med. 145:758-764.
7. Boaz, A., et al. 2000. Pseudomembranous colitis: report of a severe case with unusual clinical signs in a young nurse. Dis. Colon Rectum 43:264-266.
8. Borriello, S. P. 1998. Pathogenesis of Clostridium difficile infection. J. Antimicrob. Chemother. 41(Suppl. C):13-19.
9. Chen, X., et al. 2008. A mouse model of Clostridium difficile-associated disease. Gastroenterology 135:1984-1992.
10. Cloud, J., and C. P. Kelly. 2007. Update on Clostridium difficile associated disease. Curr. Opin. Gastroenterol. 23:4-9.
11. Cunney, R. J., C. Magee, E. McNamara, E. G. Smyth, and J. Walshe. 1998. Clostridium difficile colitis associated with chronic renal failure. Nephrol. Dial. Transplant. 13:2842-2846.
12. Czuprynski, C. J., W. J. Johnson, E. Balish, and T. Wilkins. 1983. Pseudomembranous colitis in Clostridium difficile-monoassociated rats. Infect. Immun. 39:1368-1376.
13. Fekety, R., et al. 1979. Antibiotic-associated colitis: effects of antibiotics on Clostridium difficile and the disease in hamsters. Rev. Infect. Dis. 1:386-397.
14. He, X., et al. 2009. An ultrasensitive rapid immunocytotoxicity assay for detecting Clostridium difficile toxins. J. Microbiol. Methods 78:97-100.
15. Jafri, S. F., and J. B. Marshall. 1996. Ascites associated with antibioticassociated pseudomembranous colitis. South. Med. J. 89:1014-1017.
16. Johnson, S. 2009. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J. Infect. 58:403-410.
17. Johnson, S. 2009. Recurrent Clostridium difficile infection: causality and therapeutic approaches. Int. J. Antimicrob. Agents 33(Suppl. 1):S33-S36.
18. Johnson, S., A. Adelmann, C. R. Clabots, L. R. Peterson, and D. N. Gerding. 1989. Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism. J. Infect. Dis. 159:340-343.
19. Kink, J. A., and J. A. Williams. 1998. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect. Immun. 66:2018-2025.
20. Knoop, F. C. 1979. Clindamycin-associated enterocolitis in guinea pigs: evidence for a bacterial toxin. Infect. Immun. 23:31-33.
21. Kyne, L., M. Warny, A. Qamar, and C. P. Kelly. 2001. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357:189-193.
22. Kyne, L., M. Warny, A. Qamar, and C. P. Kelly. 2000. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N. Engl. J. Med. 342:390-397.
23. Lawley, T. D., et al. 2009. Antibiotic treatment of Clostridium difficile carrier mice triggers a supershedder state, spore-mediated transmission, and severe disease in immunocompromised hosts. Infect. Immun. 77:3661-3669.
24. Loo, V. G., et al. 2005. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 353:2442-2449.
25. Lyerly, D. M., K. E. Saum, D. K. MacDonald, and T. D. Wilkins. 1985. Effects of Clostridium difficile toxins given intragastrically to animals. Infect. Immun. 47:349-352.
26. McDonald, L. C., et al. 2005. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 353:2433-2441.
27. McFarland, L. V., G. W. Elmer, and C. M. Surawicz. 2002. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am. J. Gastroenterol. 97:1769-1775.
28. O'Neill, G. L., M. H. Beaman, and T. V. Riley. 1991. Relapse versus reinfection with Clostridium difficile. Epidemiol. Infect. 107:627-635.
29. Pawlowski, S. W., et al. 2010. Murine model of Clostridium difficile infection with aged gnotobiotic C57BL/6 mice and a BI/NAP1 strain. J. Infect. Dis. 202:1708-1712.
30. Sakurai, T., et al. 2001. Liver abscess caused by Clostridium difficile. Scand. J. Infect. Dis. 33:69-70.
31. Sorg, J. A., and A. L. Sonenshein. 2010. Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid. J. Bacteriol. 192:4983-4990.
32. Steele, J., H. Feng, N. Parry, and S. Tzipori. 2010. Piglet models of acute or chronic Clostridium difficile illness. J. Infect. Dis. 201:428-434.
33. Tang-Feldman, Y., S. Mayo, J. Silva, Jr., and S. H. Cohen. 2003. Molecular analysis of Clostridium difficile strains isolated from 18 cases of recurrent Clostridium difficile-associated diarrhea. J. Clin. Microbiol. 41:3413-3414.
34. Tonna, I., and P. D. Welsby. 2005. Pathogenesis and treatment of Clostridium difficile infection. Postgrad. Med. J. 81:367-369.
35. Warny, M., J. P. Vaerman, V. Avesani, and M. Delmee. 1994. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect. Immun. 62:384-389.
36. Wilcox, M. H., W. N. Fawley, C. D. Settle, and A. Davidson. 1998. Recurrence of symptoms in Clostridium difficile infection-relapse or reinfection? J. Hosp. Infect. 38:93-100.
37. Zar, F. A., S. R. Bakkanagari, K. M. L. S. T. Moorthi, and M. B. Davis. 2007. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin. Infect. Dis. 45:302-307.
38. Zwiener, R. J., W. M. Belknap, and R. Quan. 1989. Severe pseudomembranous enterocolitis in a child: case report and literature review. Pediatr. Infect. Dis. J. 8:876-882.